Oncology

Live Report from ASH:
Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

Pierre Fenaux
Pierre Fenaux

PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.

Download this interview

Similar Interviews

  • Audio Journal of Oncology in Advance - March 1st, 2008
  • Volume 16 Number 5 (March 1st, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) Gastrointestinal Cancers Symposium

  • Audio Journal of Cardiovascular Medicine: June 2006 - In the company of Michael Petch">Audio Journal of Cardiovascular Medicine: June 2006 - In the company of Michael Petch
  • Annual Meeting of the American College of Cardiology March 11-14, 2006, Atlanta: Single Agent Bivalirudin Better for Acute Coronary Syndromes;

  • Audio Journal of Oncology in Advance - February 1st, 2007 - reporting from American Society of Hematology 48th Annual Meeting, December 9-12, 2006 Orlando">Audio Journal of Oncology in Advance - February 1st, 2007 - reporting from American Society of Hematology 48th Annual Meeting, December 9-12, 2006 Orlando
  • Francis Giles

    Post a comment

    Subscribe to Audio Medica Podcast